STAAR Surgical (STAA) Shares Sold by American International Group Inc.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Quantum Capital Management grew its …

STAAR Surgical logoAmerican International Group Inc. lowered its stake in shares of STAAR Surgical (NASDAQ:STAA) by 3.1% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 28,033 shares of the medical instruments supplier’s stock after selling 908 shares during the period. American International Group Inc. owned approximately 0.06% of STAAR Surgical worth $958,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Quantum Capital Management grew its stake in shares of STAAR Surgical by 45.8% during the first quarter. Quantum Capital Management now owns 72,655 shares of the medical instruments supplier’s stock valued at $2,484,000 after purchasing an additional 22,809 shares during the last quarter. Victory Capital Management Inc. bought a new stake in shares of STAAR Surgical during the first quarter valued at approximately $186,000. Comerica Bank grew its stake in shares of STAAR Surgical by 7.5% during the first quarter. Comerica Bank now owns 37,197 shares of the medical instruments supplier’s stock valued at $1,377,000 after purchasing an additional 2,600 shares during the last quarter. Robeco Institutional Asset Management B.V. grew its stake in shares of STAAR Surgical by 371.9% during the first quarter. Robeco Institutional Asset Management B.V. now owns 32,502 shares of the medical instruments supplier’s stock valued at $1,112,000 after purchasing an additional 25,614 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in shares of STAAR Surgical by 4.4% during the first quarter. Rhumbline Advisers now owns 71,947 shares of the medical instruments supplier’s stock valued at $2,460,000 after purchasing an additional 3,038 shares during the last quarter. 89.59% of the stock is owned by institutional investors and hedge funds.

In other STAAR Surgical news, CEO Caren L. Mason sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $36.25, for a total value of $271,875.00. Following the transaction, the chief executive officer now directly owns 44,013 shares of the company’s stock, valued at $1,595,471.25. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Broadwood Partners, L.P. acquired 100,000 shares of STAAR Surgical stock in a transaction on Friday, May 3rd. The stock was acquired at an average cost of $22.23 per share, for a total transaction of $2,223,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 17,730 shares of company stock worth $655,538. Insiders own 3.90% of the company’s stock.

Several research firms have recently commented on STAA. Zacks Investment Research cut shares of STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Saturday, March 2nd. BidaskClub raised shares of STAAR Surgical from a “hold” rating to a “buy” rating in a research note on Friday, March 22nd. ValuEngine cut shares of STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Thursday, April 18th. Finally, Canaccord Genuity reissued a “buy” rating and set a $38.00 price target (down from $43.00) on shares of STAAR Surgical in a research note on Monday, May 6th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the stock. STAAR Surgical presently has a consensus rating of “Buy” and an average price target of $40.33.

Shares of STAA stock opened at $27.08 on Friday. STAAR Surgical has a 52-week low of $21.70 and a 52-week high of $54.00. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of 96.71 and a beta of 2.23. The company has a current ratio of 5.41, a quick ratio of 4.83 and a debt-to-equity ratio of 0.04.

STAAR Surgical (NASDAQ:STAA) last announced its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.06. STAAR Surgical had a net margin of 4.44% and a return on equity of 13.22%. The firm had revenue of $32.58 million for the quarter, compared to analysts’ expectations of $32.40 million. During the same period last year, the firm earned $0.01 earnings per share. As a group, equities analysts anticipate that STAAR Surgical will post 0.33 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “STAAR Surgical (STAA) Shares Sold by American International Group Inc.” was reported by Tech Know Bits and is the property of of Tech Know Bits. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://techknowbits.com/2019/06/08/staar-surgical-staa-shares-sold-by-american-international-group-inc.html.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Read More: What do I need to know about analyst ratings?

Institutional Ownership by Quarter for STAAR Surgical (NASDAQ:STAA)

Receive News & Ratings for STAAR Surgical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for STAAR Surgical and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Acadian Asset Management LLC Has $2.57 Million Position in STAAR Surgical (STAA)

Acadian Asset Management LLC reduced its stake in shares of STAAR Surgical (NASDAQ:STAA) by 44.5% during the 1st quarter, according to the …

STAAR Surgical logoAcadian Asset Management LLC reduced its stake in shares of STAAR Surgical (NASDAQ:STAA) by 44.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 75,217 shares of the medical instruments supplier’s stock after selling 60,350 shares during the quarter. Acadian Asset Management LLC owned 0.17% of STAAR Surgical worth $2,572,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in STAA. Morgan Stanley increased its position in STAAR Surgical by 8.8% during the 3rd quarter. Morgan Stanley now owns 102,790 shares of the medical instruments supplier’s stock valued at $4,935,000 after purchasing an additional 8,295 shares during the period. Bank of Montreal Can increased its position in STAAR Surgical by 903.3% during the 4th quarter. Bank of Montreal Can now owns 3,050 shares of the medical instruments supplier’s stock valued at $97,000 after purchasing an additional 2,746 shares during the period. Strs Ohio increased its position in STAAR Surgical by 1.2% during the 4th quarter. Strs Ohio now owns 24,800 shares of the medical instruments supplier’s stock valued at $791,000 after purchasing an additional 300 shares during the period. Xact Kapitalforvaltning AB increased its position in STAAR Surgical by 31.0% during the 4th quarter. Xact Kapitalforvaltning AB now owns 7,600 shares of the medical instruments supplier’s stock valued at $243,000 after purchasing an additional 1,800 shares during the period. Finally, Advisors Asset Management Inc. increased its position in STAAR Surgical by 102.1% during the 4th quarter. Advisors Asset Management Inc. now owns 12,708 shares of the medical instruments supplier’s stock valued at $406,000 after purchasing an additional 6,420 shares during the period. Institutional investors and hedge funds own 89.59% of the company’s stock.

In other news, insider Samuel J. Gesten sold 1,500 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $36.20, for a total value of $54,300.00. Following the sale, the insider now directly owns 36,816 shares in the company, valued at approximately $1,332,739.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Broadwood Partners, L.P. purchased 100,000 shares of the stock in a transaction dated Friday, May 3rd. The stock was purchased at an average price of $22.23 per share, for a total transaction of $2,223,000.00. The disclosure for this purchase can be found here. Insiders sold a total of 17,730 shares of company stock worth $655,538 over the last 90 days. Company insiders own 3.90% of the company’s stock.

A number of research analysts have commented on the stock. BidaskClub raised shares of STAAR Surgical from a “hold” rating to a “buy” rating in a research report on Wednesday, February 20th. ValuEngine downgraded shares of STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, April 18th. Canaccord Genuity reissued a “buy” rating and set a $38.00 target price (down previously from $43.00) on shares of STAAR Surgical in a research report on Monday, May 6th. Finally, Zacks Investment Research raised shares of STAAR Surgical from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a research report on Wednesday, May 1st. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $40.33.

NASDAQ STAA opened at $23.08 on Tuesday. The company has a current ratio of 5.41, a quick ratio of 4.83 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of 82.43 and a beta of 2.23. STAAR Surgical has a one year low of $21.70 and a one year high of $54.00.

STAAR Surgical (NASDAQ:STAA) last released its quarterly earnings results on Wednesday, May 1st. The medical instruments supplier reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.06. STAAR Surgical had a net margin of 4.44% and a return on equity of 13.22%. The business had revenue of $32.58 million for the quarter, compared to analysts’ expectations of $32.40 million. During the same period last year, the business earned $0.01 EPS. On average, equities research analysts expect that STAAR Surgical will post 0.3 EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Rockland Register and is owned by of Rockland Register. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://rocklandregister.com/2019/06/04/acadian-asset-management-llc-has-2-57-million-position-in-staar-surgical-staa.html.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Featured Story: What is the formula for the cash asset ratio?

Institutional Ownership by Quarter for STAAR Surgical (NASDAQ:STAA)

Receive News & Ratings for STAAR Surgical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for STAAR Surgical and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

STAAR Surgical (STAA) Upgraded at Zacks Investment Research

Quantum Capital Management grew its stake in STAAR Surgical by 45.8% during the first quarter. Quantum Capital Management now owns 72,655 …

STAAR Surgical logoZacks Investment Research upgraded shares of STAAR Surgical (NASDAQ:STAA) from a hold rating to a strong-buy rating in a research note published on Tuesday morning, Zacks.com reports. The brokerage currently has $29.00 price target on the medical instruments supplier’s stock.

According to Zacks, “Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma. “

Other equities analysts also recently issued reports about the stock. BidaskClub upgraded shares of STAAR Surgical from a hold rating to a buy rating in a research note on Wednesday, February 20th. Canaccord Genuity restated a buy rating and issued a $38.00 price target (down from $43.00) on shares of STAAR Surgical in a research note on Monday. Finally, ValuEngine upgraded shares of STAAR Surgical from a hold rating to a buy rating in a research note on Wednesday, May 1st. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. STAAR Surgical has a consensus rating of Buy and an average price target of $40.33.

Shares of STAA traded down $1.30 during trading hours on Tuesday, hitting $25.96. The company had a trading volume of 27,435 shares, compared to its average volume of 447,169. The firm has a market capitalization of $1.21 billion, a PE ratio of 91.82 and a beta of 2.02. STAAR Surgical has a 12 month low of $21.70 and a 12 month high of $54.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 5.41 and a quick ratio of 4.83.

STAAR Surgical (NASDAQ:STAA) last issued its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported $0.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.04 by $0.06. The company had revenue of $32.58 million for the quarter, compared to analyst estimates of $32.40 million. STAAR Surgical had a net margin of 4.44% and a return on equity of 13.22%. During the same period in the prior year, the firm earned $0.01 earnings per share. Analysts predict that STAAR Surgical will post 0.33 earnings per share for the current fiscal year.

In other STAAR Surgical news, CTO Keith Holliday sold 2,084 shares of the stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $36.22, for a total transaction of $75,482.48. Following the sale, the chief technology officer now directly owns 40,239 shares in the company, valued at $1,457,456.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Broadwood Partners, L.P. acquired 100,000 shares of STAAR Surgical stock in a transaction on Friday, May 3rd. The shares were purchased at an average price of $22.23 per share, for a total transaction of $2,223,000.00. The disclosure for this purchase can be found here. Insiders sold 17,730 shares of company stock worth $655,538 over the last 90 days. 3.90% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the business. Great West Life Assurance Co. Can grew its stake in STAAR Surgical by 46.8% during the first quarter. Great West Life Assurance Co. Can now owns 5,172 shares of the medical instruments supplier’s stock worth $176,000 after buying an additional 1,649 shares in the last quarter. Cadence Capital Management LLC grew its stake in STAAR Surgical by 66.7% during the first quarter. Cadence Capital Management LLC now owns 113,410 shares of the medical instruments supplier’s stock worth $3,877,000 after buying an additional 45,387 shares in the last quarter. Quantum Capital Management grew its stake in STAAR Surgical by 45.8% during the first quarter. Quantum Capital Management now owns 72,655 shares of the medical instruments supplier’s stock worth $2,484,000 after buying an additional 22,809 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in STAAR Surgical during the first quarter worth about $186,000. Finally, Comerica Bank grew its stake in STAAR Surgical by 7.5% during the first quarter. Comerica Bank now owns 37,197 shares of the medical instruments supplier’s stock worth $1,377,000 after buying an additional 2,600 shares in the last quarter. Hedge funds and other institutional investors own 90.99% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Read More: What is a resistance level?

Get a free copy of the Zacks research report on STAAR Surgical (STAA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for STAAR Surgical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for STAAR Surgical and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

STAAR Surgical (NASDAQ:STAA) Posts Earnings Results, Beats Estimates By $0.06 EPS

Quantum Capital Management increased its position in STAAR Surgical by 45.8% during the 1st quarter. Quantum Capital Management now owns …

STAAR Surgical logoSTAAR Surgical (NASDAQ:STAA) announced its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported $0.10 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.06, RTT News reports. The company had revenue of $32.58 million for the quarter, compared to analysts’ expectations of $32.40 million. STAAR Surgical had a net margin of 4.44% and a return on equity of 13.22%. During the same quarter in the previous year, the company posted $0.01 EPS.

Shares of STAA stock traded down $0.04 during trading on Thursday, hitting $27.26. 264,231 shares of the company were exchanged, compared to its average volume of 447,169. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.83 and a current ratio of 5.41. The stock has a market cap of $1.11 billion, a P/E ratio of 97.36 and a beta of 2.02. STAAR Surgical has a twelve month low of $21.70 and a twelve month high of $54.00.

In related news, CTO Keith Holliday sold 2,084 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $36.22, for a total transaction of $75,482.48. Following the completion of the sale, the chief technology officer now directly owns 40,239 shares in the company, valued at $1,457,456.58. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Samuel J. Gesten sold 1,500 shares of STAAR Surgical stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $36.20, for a total transaction of $54,300.00. Following the completion of the sale, the insider now owns 36,816 shares of the company’s stock, valued at $1,332,739.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 17,730 shares of company stock valued at $655,538. 3.90% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of STAA. Great West Life Assurance Co. Can increased its position in STAAR Surgical by 46.8% during the 1st quarter. Great West Life Assurance Co. Can now owns 5,172 shares of the medical instruments supplier’s stock worth $176,000 after buying an additional 1,649 shares during the period. Cadence Capital Management LLC increased its position in STAAR Surgical by 66.7% during the 1st quarter. Cadence Capital Management LLC now owns 113,410 shares of the medical instruments supplier’s stock worth $3,877,000 after buying an additional 45,387 shares during the period. Quantum Capital Management increased its position in STAAR Surgical by 45.8% during the 1st quarter. Quantum Capital Management now owns 72,655 shares of the medical instruments supplier’s stock worth $2,484,000 after buying an additional 22,809 shares during the period. Victory Capital Management Inc. bought a new position in STAAR Surgical during the 1st quarter worth $186,000. Finally, Comerica Bank increased its position in shares of STAAR Surgical by 7.5% in the first quarter. Comerica Bank now owns 37,197 shares of the medical instruments supplier’s stock worth $1,377,000 after purchasing an additional 2,600 shares during the period. Hedge funds and other institutional investors own 90.99% of the company’s stock.

STAA has been the topic of several recent research reports. BidaskClub raised shares of STAAR Surgical from a “sell” rating to a “hold” rating in a research note on Wednesday, January 9th. Zacks Investment Research cut shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Saturday, March 2nd. ValuEngine cut shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Thursday, April 18th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $38.00 target price (down from $43.00) on shares of STAAR Surgical in a report on Monday. One analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. STAAR Surgical presently has an average rating of “Buy” and a consensus price target of $40.33.

TRADEMARK VIOLATION NOTICE: This piece was first published by Tech Know Bits and is the sole property of of Tech Know Bits. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://techknowbits.com/2019/05/09/staar-surgical-staa-releases-quarterly-earnings-results-beats-expectations-by-0-06-eps.html.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Featured Article: Percentage Gainers

Earnings History for STAAR Surgical (NASDAQ:STAA)

Receive News & Ratings for STAAR Surgical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for STAAR Surgical and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

STAAR Surgical (NASDAQ:STAA) Releases Earnings Results, Beats Expectations By $0.06 EPS

Quantum Capital Management lifted its position in shares of STAAR Surgical by 45.8% during the first quarter. Quantum Capital Management now …

STAAR Surgical logoSTAAR Surgical (NASDAQ:STAA) announced its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported $0.10 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.06, RTT News reports. The company had revenue of $32.58 million during the quarter, compared to analysts’ expectations of $32.40 million. STAAR Surgical had a net margin of 4.44% and a return on equity of 13.22%. During the same quarter in the prior year, the company earned $0.01 EPS.

Shares of STAAR Surgical stock traded down $0.04 on Thursday, hitting $27.26. 281,505 shares of the company traded hands, compared to its average volume of 447,169. STAAR Surgical has a 52 week low of $21.70 and a 52 week high of $54.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 5.41 and a quick ratio of 4.83. The stock has a market cap of $1.11 billion, a P/E ratio of 97.21 and a beta of 2.02.

A number of brokerages have recently issued reports on STAA. Zacks Investment Research downgraded shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Saturday, March 2nd. BidaskClub upgraded shares of STAAR Surgical from a “hold” rating to a “buy” rating in a research note on Friday, March 22nd. ValuEngine cut shares of STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Thursday, April 18th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $38.00 price objective (down previously from $43.00) on shares of STAAR Surgical in a research note on Monday. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. STAAR Surgical presently has a consensus rating of “Buy” and a consensus price target of $40.33.

In other STAAR Surgical news, CTO Keith Holliday sold 3,125 shares of STAAR Surgical stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $38.89, for a total transaction of $121,531.25. Following the completion of the transaction, the chief technology officer now directly owns 40,239 shares of the company’s stock, valued at $1,564,894.71. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Broadwood Partners, L.P. acquired 100,000 shares of the company’s stock in a transaction on Friday, May 3rd. The shares were purchased at an average cost of $22.23 per share, with a total value of $2,223,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders sold 17,730 shares of company stock valued at $655,538. 3.90% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Great West Life Assurance Co. Can lifted its position in shares of STAAR Surgical by 46.8% during the first quarter. Great West Life Assurance Co. Can now owns 5,172 shares of the medical instruments supplier’s stock worth $176,000 after purchasing an additional 1,649 shares during the last quarter. Cadence Capital Management LLC lifted its position in shares of STAAR Surgical by 66.7% during the first quarter. Cadence Capital Management LLC now owns 113,410 shares of the medical instruments supplier’s stock worth $3,877,000 after purchasing an additional 45,387 shares during the last quarter. Quantum Capital Management lifted its position in shares of STAAR Surgical by 45.8% during the first quarter. Quantum Capital Management now owns 72,655 shares of the medical instruments supplier’s stock worth $2,484,000 after purchasing an additional 22,809 shares during the last quarter. Victory Capital Management Inc. bought a new stake in shares of STAAR Surgical during the first quarter worth $186,000. Finally, Comerica Bank lifted its position in shares of STAAR Surgical by 7.5% during the first quarter. Comerica Bank now owns 37,197 shares of the medical instruments supplier’s stock worth $1,377,000 after purchasing an additional 2,600 shares during the last quarter. 90.99% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “STAAR Surgical (NASDAQ:STAA) Releases Earnings Results, Beats Expectations By $0.06 EPS” was originally reported by Mayfield Recorder and is owned by of Mayfield Recorder. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://mayfieldrecorder.com/2019/05/09/staar-surgical-staa-announces-earnings-results.html.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Featured Story: Average Daily Trade Volume – What It Means In Stock Trading

Earnings History for STAAR Surgical (NASDAQ:STAA)

Receive News & Ratings for STAAR Surgical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for STAAR Surgical and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts